Join the club for FREE to access the whole archive and other member benefits.

Guy Charles Fanneau de la Horie

Independent Board member including Angels Santé and Genflow Biosciences

Over the past 20 years, Guy-Charles has built, and led, biotech executive teams where he has acted as Chief Executive Officer. During his tenures, he has successfully led IPOs and completed multiple fundraisings. Guy-Charles’ expertise in the biotech field in both public and private companies encompasses launching and selling new drugs in untapped markets, with successful early access programs. 

Specifically, Guy-Charles has served as Chief Executive Officer at three biotech companies, including, until very recently, Euronext Growth traded, Pherecydes Pharma, a biotech company that develops treatments against resistant bacterial infections; and Neovacs, a therapeutic vaccine company. Guy-Charles has also held senior positions at Biogen, a Nasdaq listed global biotechnology company. Guy-Charles managed the IPO and associated successful financing of Neovacs in 2010, and in 2021, led Pherecydes Pharma through an oversubscribed placing.

Visit website: https://genflowbio.com/leadership/#guy

 guy-charles-fanneau-de-la-horie-9294597

See also: Company Genflow Biosciences - Developing medicines that potentially halt, slow or reverse the aging process

Details last updated 20-Aug-2022

Guy Charles Fanneau de la Horie is also referenced in the following:

Genflow Biosciences

Developing medicines that potentially halt, slow or reverse the aging process